A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase II Study of Weekly Oral Methotrexate and Zidovudine (AZT) in Advanced Adenocarcinoma of the Pancreas and Hepatocellular Carcinoma
Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers
Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Study
Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis
Activity of 2 Methoxyestradiol (Panzem® NCD) in Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis
A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results
A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GEJ junction carcinomas
A Prospective Randomized Trial of Fluorouracil Versus Fluorouracil plus Cisplatin in the Treatment of Metastatic Colorectal Cancer
Prophylactic 32P Chromic Phosphate Therapy of the Liver in Completely Resected Modified Duke’s Stage C Colon Cancers
A Prospective Randomized Trial of 5-Fluorouracil versus 5-Fluorouracil plus Levamisole in the Treatment of Metastatic Colorectal Cancer
A Phase II Trial of Irinotecan, 5-Fluorouracil, Leucovorin, combined with Celecoxib and Glutamine as first line therapy for advanced colorectal cancer
Phase II Trial of Neoadjuvant Capecitabine (Cp) with Irinotecan (Ir) followed by Capecitabine-based Chemoradiotherapy (CRT) for Patients (pts) with Locally Advanced Rectal Cancer (LARC)
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer
Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC) in Metastatic Breast Cancer: A Phase II Trial
Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer
Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer
Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making: BRE02-43
A large, consistent plasma proteomics data set from prospectively collected breast cancer patient and healthy volunteer samples
A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane-containing regimen
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer
A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC). A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer
Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial
Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
BRE12-158: A Post-neoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician’s Choice for Patients with Residual Triple-Negative Breast Cancer
Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Study
Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression
Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade
